Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial - 07/06/16

Doi : 10.1016/S1470-2045(16)00107-8 
Gillian M Duchesne, ProfMD a, , Henry H Woo, MB BS b, Julie K Bassett, PhD c, Steven J Bowe, PhD d, Catherine D’Este, ProfPhD e, Mark Frydenberg, MB BS f, Madeleine King, ProfPhD g, Leo Ledwich c, Andrew Loblaw, ProfMD h, Shawn Malone, FRCPC i, Jeremy Millar, FRANZCR j, Roger Milne, PhD c, Rosemary G Smith, GradDip c, Nigel Spry, ProfPhD k, Martin Stockler, ProfMB BS l, Rodney A Syme, FRACS m, , Keen Hun Tai, FRANZCR a, Sandra Turner, MB BS n
a Peter MacCallum Cancer Centre and Melbourne University, Melbourne, VIC, Australia 
b Sydney Adventist Hospital Clinical School, University of Sydney, Sydney, NSW, Australia 
c Cancer Council Victoria, Melbourne, VIC, Australia 
d Deakin Biostatistics Unit, Faculty of Health, Deakin University, Melbourne, VIC, Australia 
e National Centre for Epidemiology and Population Health, Australian National University College of Medicine, Canberra, ACT, Australia 
f Department of Surgery, Monash University Faculty of Medicine, Clayton, VIC, Australia 
g School of Psychology, Sydney Medical School and Chris O’Brien Lifehouse, University of Sydney, Sydney, NSW, Australia 
h Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, ON, Canada 
i The Ottawa Hospital, Ottawa, ON, Canada 
j Radiation Oncology, Alfred Health, Melbourne, VIC, Australia 
k Sir Charles Gairdner Hospital, Nedlands, WA, Australia 
l NHMRC Clinical Trials Unit, University of Sydney, Camperdown, NSW, Australia 
m Department of Surgery, The Austin Hospital and University of Melbourne, Melbourne, VIC, Australia 
n Department of Radiation Oncology, Crown Princess Mary Cancer Centre, Westmead, NSW, Australia 

* Correspondence to: Prof Gillian M Duchesne, Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne University, Melbourne, VIC 8006, Australia Division of Radiation Oncology Peter MacCallum Cancer Centre Melbourne University Melbourne VIC 8006 Australia



Androgen-deprivation therapy is offered to men with prostate cancer who have a rising prostate-specific antigen after curative therapy (PSA relapse) or who are considered not suitable for curative treatment; however, the optimal timing for its introduction is uncertain. We aimed to assess whether immediate androgen-deprivation therapy improves overall survival compared with delayed therapy.


In this randomised, multicentre, phase 3, non-blinded trial, we recruited men through 29 oncology centres in Australia, New Zealand, and Canada. Men with prostate cancer were eligible if they had a PSA relapse after previous attempted curative therapy (radiotherapy or surgery, with or without postoperative radiotherapy) or if they were not considered suitable for curative treatment (because of age, comorbidity, or locally advanced disease). We used a database-embedded, dynamically balanced, randomisation algorithm, coordinated by the Cancer Council Victoria, to randomly assign participants (1:1) to immediate androgen-deprivation therapy (immediate therapy arm) or to delayed androgen-deprivation therapy (delayed therapy arm) with a recommended interval of at least 2 years unless clinically contraindicated. Randomisation for participants with PSA relapse was stratified by type of previous therapy, relapse-free interval, and PSA doubling time; randomisation for those with non-curative disease was stratified by metastatic status; and randomisation in both groups was stratified by planned treatment schedule (continuous or intermittent) and treatment centre. Clinicians could prescribe any form and schedule of androgen-deprivation therapy and group assignment was not masked. The primary outcome was overall survival in the intention-to-treat population. The trial closed to accrual in 2012 after review by the independent data monitoring committee, but data collection continued for 18 months until Feb 26, 2014. It is registered with the Australian New Zealand Clinical Trials Registry (ACTRN12606000301561) and ClinicalTrials.gov (NCT00110162).


Between Sept 3, 2004, and July 13, 2012, we recruited 293 men (261 with PSA relapse and 32 with non-curable disease). We randomly assigned 142 men to the immediate therapy arm and 151 to the delayed therapy arm. Median follow-up was 5 years (IQR 3·3–6·2) from the date of randomisation. 16 (11%) men died in the immediate therapy arm and 30 (20%) died in the delayed therapy arm. 5-year overall survival was 86·4% (95% CI 78·5–91·5) in the delayed therapy arm versus 91·2% (84·2–95·2) in the immediate therapy arm (log-rank p=0·047). After Cox regression, the unadjusted HR for overall survival for immediate versus delayed arm assignment was 0·55 (95% CI 0·30–1·00; p=0·050). 23 patients had grade 3 treatment-related adverse events. 105 (36%) men had adverse events requiring hospital admission; none of these events were attributable to treatment or differed between treatment-timing groups. The most common serious adverse events were cardiovascular, which occurred in nine (6%) patients in the delayed therapy arm and 13 (9%) in the immediate therapy arm.


Immediate receipt of androgen-deprivation therapy significantly improved overall survival compared with delayed intervention in men with PSA-relapsed or non-curable prostate cancer. The results provide benchmark evidence of survival rates and morbidity to discuss with men when considering their treatment options.


Australian National Health and Medical Research Council and Cancer Councils, The Royal Australian and New Zealand College of Radiologists, Mayne Pharma Australia.

Le texte complet de cet article est disponible en PDF.


© 2016  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer

    Export citations

  • Fichier

  • Contenu

Vol 17 - N° 6

P. 727-737 - juin 2016 Retour au numéro
Article précédent Article précédent
  • Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
  • Kei Muro, Hyun Cheol Chung, Veena Shankaran, Ravit Geva, Daniel Catenacci, Shilpa Gupta, Joseph Paul Eder, Talia Golan, Dung T Le, Barbara Burtness, Autumn J McRee, Chia-Chi Lin, Kumudu Pathiraja, Jared Lunceford, Kenneth Emancipator, Jonathan Juco, Minori Koshiji, Yung-Jue Bang
| Article suivant Article suivant
  • Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
  • Andrea Sartore-Bianchi, Livio Trusolino, Cosimo Martino, Katia Bencardino, Sara Lonardi, Francesca Bergamo, Vittorina Zagonel, Francesco Leone, Ilaria Depetris, Erika Martinelli, Teresa Troiani, Fortunato Ciardiello, Patrizia Racca, Andrea Bertotti, Giulia Siravegna, Valter Torri, Alessio Amatu, Silvia Ghezzi, Giovanna Marrapese, Laura Palmeri, Emanuele Valtorta, Andrea Cassingena, Calogero Lauricella, Angelo Vanzulli, Daniele Regge, Silvio Veronese, Paolo M Comoglio, Alberto Bardelli, Silvia Marsoni, Salvatore Siena

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte

Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.

Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.